IOVANCE BIOTHERAPEUTICS UK LTD
Get an alert when IOVANCE BIOTHERAPEUTICS UK LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-02-02 (in 9mo)
Last made up 2026-01-19
Watchouts
None on the register
Accounts
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of twelve months from when the financial statements are authorised for issue.”
Group structure
- IOVANCE BIOTHERAPEUTICS UK LTD · parent
- Iovance Biotherapeutics UK SP Ltd 100%
Significant events
- “In March 2024, the Food and Drug Administration (FDA) granted regulatory approval for the development of Amtagvi®. This triggered a milestone payment of £41,670,000 as a consequence of the approval.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 1 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ROCHE, Corleen Marie | Director | 2025-08-06 | Oct 1965 | American |
| VOGT, Frederick | Director | 2023-01-20 | Aug 1973 | American |
Show 1 resigned officer
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BELLEMIN, Jean-Marc | Director | 2023-01-20 | 2025-06-30 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Iovance Biotherapeutics, Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2023-01-20 | Active |
Filing timeline
Last 12 of 12 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-10-21 | AA | accounts | Accounts with accounts type full | |
| 2025-09-08 | AP01 | officers | Appoint person director company with name date | |
| 2025-09-05 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-18 | AA | accounts | Accounts with accounts type full | |
| 2025-02-06 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2025-01-31 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-11-15 | AA01 | accounts | Change account reference date company previous shortened | |
| 2024-11-15 | SH01 | capital | Capital allotment shares | |
| 2024-01-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-06-12 | AD01 | address | Change registered office address company with date old address new address | |
| 2023-01-20 | NEWINC | incorporation | Incorporation company |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 1
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
Latest filed period vs the prior one